Bispecific Antibodies

Handbook of Therapeutic Antibodies

Volumn 2, Issue , 2008, Pages 345-378

  Müller, Dafne ^a   Kontermann, Roland E ^a  

^a UNIVERSITY OF STUTTGART   (Germany)

Author keywords

Bispecifi c antibodies; Hybrid myeloma; Hybridization; Immunoblotting; Molecules

Indexed keywords

EID: 34547131350     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527619740.ch15     Document Type: Chapter

References (176)

1. Alt, M., Müller, R., Kontermann, R.E. (1999) Novel tetravalent and bispecific IgG-like antibody molecules combining single-chain diabodies with the immunoglobulin γ1 Fc or CH3 region. FEBS Lett 454: 90-94.
2. Atwell, S., Ridgway, J.B.B., Wells, J.A., Carter, P. (1997) Stable heterodimers from remodelling the domain interface of a homodimer using a phage display library. J Mol Biol 270: 26-35.
3. Amoroso, R.A., Alpaugh, R.K., Barth, M.W., McCall, A.M., Weiner, L.M. (1999) Production and characterization of mice transgenic for the A and B isoforms of human FcγRIII. Cancer Immunol Immunother 48: 443-455.
4. Barnett, B.G., Crews, C.J., Douglas, J.T. (2002) Targeted adenoviral vectors. Biochim Biophys Acta 1575: 1-14.
5. Bartlett, J.S., Kleinschmidt, J., Boucher, R. C., Samulski, R.J. (1999) Targeted adenoassociated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab′γ)2 antibody. Nat Biotechnol 17: 181-186.
6. Bartsch, M., Weeke-Klimp, A.H., Meijer, D. K., Scherphof, G.L., Kamps, J.A. (2005) Cell-specific targeting of lipid-based carriers for ODN and DNA. J Liposome Res 15: 59-92.
7. Biburger, M., Weth, R., Wels, W.S. (2005) A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2. J Mol Biol 346: 1299-1311.
8. Blanco, B., Holliger, P., Vile, R.G., Álvarez-Vallina, L. (2003) Induction of human T lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific d iabody-based molecules secreted from gene-modified bystander cells. J Immunol 171: 1070-1077.
9. Bonardi, M.A., Bell, A., Fench, R.R., Gromo, G., Hamblin, T., Modena, D., Tutt, A.L., Glennie, M.J. (1992) Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin. Int J Cancer Suppl 7: 73-77.
10. Bonardi, M.A., French, R.R., Amlot, P., Gromo, G., Modena, D., Glennie, M.J. (1993) Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing. Cancer Res 53: 3015-3021.
11. Brandão, J.G., Scheper, R.J., Lougheed, S.M., Curiel, D.T., Tillman, B.W., Gerritsen, W. R., van den Eertwegh, A.J., Pinedo, H.M., Haisma, H.J., de Gruijl, T.D. (2003) CD40targeted adenoviral gene transfer to dendritic cells through the use of a novel bispecific single-chain Fv antibody enhances cytotoxic T cell activation. Vaccine 21: 2268-2272.
12. Brekke, O.H., Sandlie, I. (2003) Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov 22: 52-62.
13. Brennan, M. (1986) A chemical technique for the preparation of bispecific antibodies from Fab fragments of mouse monoclonal IgG1. BioTechniques 4: 424-427.
14. Brennan, M., Davison, P.F., Paulus, H. (1985) Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments. Science 229: 81-83.
15. Bruenke, J., Fischer, B., Barbin, K., Schreiter, K., Wachter, Y., Mahr, K., Titgemeyer, F., Niederweis, M., Peipp, M., Zunino, S., Repp, R., Valerius, T., and Fey, G.H. (2004) A recombinant bispecific single-chain Fv antibody against HLA classII and FcγRIII (CD16) triggers effective lysis of lymphoma cells. Br J Haematol 125: 167-179.
16. Bruenke, J., Barbin, K., Kunert, S., Lang, P., Pfeiffer, M., Stieglmaier, K., Niethammer, D., Stockmeyer, B., Peipp, M., Repp, R., Valerius, T., Fey, G.H. (2005) Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16). Br J Haematol 130: 218-228.
17. Brüsselbach, S., Korn, T., Völkel, T., Müller, R., Kontermann, R.E. (1999) Enzyme recruitment and tumor cell killing in vitro by a secreted bispecific single-chain diabody. Tumor Targeting 4: 115-123.
18. Bubenik, J. (2003) Tumour MHC class I downregulation and immunotherapy. Oncol Rep 10: 2205-2208.
19. Cao, Y., Lam, L. (2003) Bispecific antibody conjugates in therapeutics. Adv Drug Deliv Rev 55: 171-197.
20. Cao, Y., Suresh, M.R. (1998) Bispecific antibodies as novel bioconjugates. Bioconjug Chem 9: 635-644.
21. Cao, Y., Vinayagamoorthy, T., Noujaim, A. A., Suresh, M.R. (1995) A rapid nonseletive method to generate quadromas by microelectrofusion. J Immunol Methods 187: 1-7.
22. Carter, P. (2001) Bispecific human IgG by design. J Immunol Methods 248: 7-15.
23. Chang, C.-H., Sharkey, R.M., Rossi, E.A., Karacay, H., McBridge, W., Hansen, H.J., Chatal, J.-F., Barbet, J., Goldenberg, D.M. (2002) Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol Cancer Ther 1: 553-563.
24. Cochlovius, B., Kipriyanov, S.M., Stassar, M.J.J.G., Schuhmacher, J., Benner A., Moldenhauer, G., Little, M. (2000) Cure of Burkitt's lymphoma in severe combined immunodeficiency mice by T cells, tetravalent CD3 × CD19 tandem diabody, and CD28 costimulation. Cancer Res 60: 4336-4341.
25. Coloma, M.J., Morrison, S.L. (1997) Design and production of novel tetravalent bispecific antibodies. Nat Biotechnol 15: 159-163.
26. Connelly, R.J., Hayden, M.S., Scholler, J.K., Tsu, T.T., Dupont, B., Ledbetter, J.A., Kanner, S.B. (1998) Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes. Int Immunol 10: 1863-1872.
27. Corvalan, J.R., Smith, W. (1987) Construction and characterisation of a hybrid-hybrid monoclonal antibody recognising both carcinoembryonic antigen (CEA) and vinca alkaloids. Cancer Immunol Immunother 24: 127-132.
28. Curnow, R.T. (1997) Clinical experience with CD64-directed immunotherapy. An overview. Cancer Immunol Immunother 45: 210-215.
29. de Gast, G.C., van de Winkel, J.G.J., Bast, B. E.J.E.G. (1997) Clinical perspectives of bispecific antibodies in cancer. Cancer Immunol Immunother 45: 121-123.
30. de Gruijl, T.D., Luykx-de Bakker, S.A., Tillman, B.W., van den Eertwegh, A.J., Buter, J., Lougheed, S.M., van der Bij, G.J., Safer, A.M., Haisma, H.J., Curiel, D.T., Scheper, R.J., Pinedo, H.M., Gerritsen, W. R. (2002) Prolonged maturation and enhanced transduction of dendritic cells migrated from human skin explants after in situ delivery of CD40-targeted adenoviral vectors. J Immunol 169: 5322-5331.
31. de Kruif, J., Logtenberg, T. (1996) Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semisynthetic antibody phage display library. J Biol Chem 271: 7630-7634.
32. De Lau, W.B., van Loon, A.E., Heije, K., Valerio, D., Bast, B.J. (1989) Production of hybrid hybridomas based on HAT(s)neomycin double mutants. J Immunol Methods 117: 1-8.
33. De Lau, W.B., Keije, K., Neefjes, J.J., Oosterwegel, M., Rozemüller, E., Blast, B.J. (1991) Absence of preferential homologous H/L chain association in hybrid hybridomas. J Immunol 146: 906-914.
34. DeNardo, D.G., Xiong, C.Y., Shi, X.B., DeNardo, G.L., DeNardo, S.J. (2001) Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy. Cancer Biother Radiopharm 16: 525-535.
35. Deo, Y.M., Sundarapandiyan, K., Keler, T., Wallace, P.K., Graziano, R.F. (1998) Bispecific molecules directed to the Fc receptor for IgA (FcαRI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood. J Immunol 160: 1677-1686.
36. Dreier, T., Baeuerle, P.A., Fichtner, I., Grün, M., Schlereth, B., Lorenczewski, G., Kufer, P., Lutterbüse, R., Riethmüller, G., Gjorstrup, P., Bargou, R.C. (2003) T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J Immunol 170: 4397-4402.
37. El-Aneed, A. (2004) An overview of current delivery systems in cancer gene therapy. J Control Release 94: 1-14.
38. Embleton, M.J., Charleston, A., Robins, R. A., Pimm, M.V., Baldwin, R.W. (1991) Recombinant ricin toxin A cytotoxicity against carcinoembryonic antigen expressing tumour cells mediated by a bispecific monoclonal antibody and its potentiation by ricin toxin chain. Br J Cancer 63: 670-674.
39. Everts, M., Curiel, D.T. (2004) Transductional targeting of adenoviral cancer gene therapy. Curr Gene Ther 4: 337-346.
40. Fanger, M.W., Guyre, P.M. (1991) Bispecific antibodies for targeted cellular cytotoxicity. Trends Biotechnol 9: 375-380.
41. Fanger, M.W., Morganelli, P.M., Guyre, P.M. (1992) Bispecific antibodies. Crit Rev Immunol 12: 101-124.
42. Ferrini, S., Sforzini, S., Canevari, S. (2001) Bispecific monoclonal antibodies for the targeting of type I ribosome-inactivating proteins against hematological malignancies. Methods Mol Biol 166: 177-192.
43. Flavell, D.J., Cooper, S., Morland, B., French, R., Flavell, S.U. (1992) Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leuaemia cell lines via CD7 and CD38 as cellular target molecules. Br J Cancer 65: 545-551.
44. FitzGerald, K., Holliger, P., Winter, G. (1997) Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng 10: 1221-1225.
45. Ford, C.H., Osborne, P.A., Rego, B.G., Mathew, A. (2001) Bispecific antibody targeting of doxorubicin to carcinoembryonic antigen-expressing colon cancer cells lines in vitro and in vivo. Int J Cancer 92: 851-855.
46. French, R.R., Penney, C.A., Browning, A.C., Stirpe, F., Georg, A.J., Glennie, M.J. (1995) Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies. Br J Cancer 71: 986-994.
47. Gautherot, E., Bouhou, J., Le Doussal, J.M., Manetti, C., Martin, M., Rouvier, E., Barbet, J. (1997) Therapy for colon carcinoma xenografts with bispecific antibody-targeted, iodine-131-labeled bivalent hapten. Cancer 80: 2618-2623.
48. Gerstmayer, B., Hoffmann, M., Altenschmidt, U., Wels, W. (1997) Costimulation of T-cell proliferation by a chimeric B7-antibody fusion protein. Cancer Immunol Immunother 45: 156-158.
49. Glennie, M.J., McBride, H.M., Worth, A.T., Stevenson, G.T. (1987) Preparation and performance of bispecific F(ab′γ)2 antibody containing thioether-linked Fab′γ fragments. J Immunol 139: 2367-2375.
50. Goldenberg, D.M. (2003) Advancing role of radiolabeled antibodies in the therapy of cancer. Cancer Immunol Immunother 52: 281-296.
51. Graziano, R.F., Guptill, P. (2004) Chemical production of bispecific antibodies. Methods Mol Biol 283: 71-85.
52. Grill, J., van Beusechem, V.W., van der Valk, P., Dirven, C.M.F., Leonhart, A., Pherai, D.S., Haisma, H.J., Pinedo, H.M., Curiel, D.T., Gerritsen, W.R. (2001) Combined targeting of adenoviruses to integrins and epidermal growth factor receptors increased gene transfer into primary glioma cells and spheroids. Clin Cancer Res 7: 641-650.
53. Grosse-Hovest, L., Hartlapp, I., Marwan, W., Brem, G., Rammensee, H.-G., Jung, G. (2003) A recombinant bispecific single-chain antibody induces targeted, supraagonistic CD28-stimulation and tumor cell killing. Eur J Immunol 33: 1334-1340.
54. Grosse-Hovest, L., Müller, S., Minoia, R., Wolf, E., Zakhartchenko, V., Wenigerkind, H., Lassnig, C., Besenfelder, U., Müller, M., Lytton, S.D., Jung, G., Brem, G. (2004) Cloned transgenic farm animals produce a bispecific antibody for T cell-mediated tumor cell killing. Proc Natl Acad Sci USA 101: 6858-6863.
55. Grosse-Hovest, L., Wick, W., Minoia, R., Weller, M., Rammensee, H.-G., Brem, G., Jung, G. (2005) Supraagonistic, bispecific single-chain antibody purified from the serum of cloned, transgenic cows induces T-cell-mediated killing of glioblastoma cells in vitro and in vivo. Int J Cancer 117: 1060-1064.
56. Gruaz-Guyon, A., Raguin, O., Barbet, J. (2005) Recent advances in pretargeted radioimmunotherapy. Curr Med Chem 12: 3319-338.
57. Haisma, H.J., Pinedo, H.M., Rijswijk, A., der Meulen-Muileman, I., Sosnowski, B. A., Ying, W., van Beusechem, V.W., Tillman, B.W., Gerritsen, W.R., Curiel, D. T. (1999) Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Ther 6: 469-474.
58. Hartmann, F., Renner, C., Jung, W., Deisting, C., Juwana, M., Eichentopf, B., Kloft, M., Pfreundschuh, M. (1997) Treatment of refractory Hodgkin's disease with an anti-CD16/CD30 bispecific antibody. Blood 89 2042-2047.
59. Hartmann, F., Renner, C., Jung, W., da Costa, L., Tembrink, S., Held, G., Sek, A., König, J., Bauer, S., Kloft, M., Pfreundschuh, M. (2001) Anti-CD16/CD30 bispecific antibody treatment for Hodgkin's disease: role of infusion schedule and costimulation with cytokines. Clin Cancer Res 7: 1873-1881.
60. Hayden, M.S., Linsley, P.S., Gayle, M.A., Bajorath, J., Brady, W.A., Norris, N.A., Fell, H.P., Ledbetter, J.A., Gilliland, L.K. (1994) Single-chain mono-and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system. Ther Immunol 1: 3-15.
61. Heideman, D.A., Snijders, P.J., Craanen, M. E., Bloemena, E., Meijer, C.J., Meuwissen, S.G., van Beusechem, V.W., Pinedo, H.M., Curiel, D.T., Haisma, H.J., Gerritsen, W.R. (2001) Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Ther 8: 342-351.
62. Hendrie, P.C., Russell, D.W. (2005) Gene targeting with viral vectors. Mol Ther 12: 9-17.
63. Heiss, M.M., Strohlein, M.A., Jäger, M., Kimmig, R., Burges, A., Schoberth, A., Jauch, K.W., Schildberg, F.W., Lindhofer, H. (2005) Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 117: 435-443.
64. Hoffmann, P., Hofmeister, R., Brischwein, K., Brandl, C., Crommer, S., Bargou, R., Itin, c., Prang, N., Baeuerle, P.A. (2005) Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3bispecific single-chain antibody construct. Int J Cancer 115: 98-104.
65. Holliger, P., Prospero, T., Winter, G. (1993) "Diabodies": small bivalent and bispecific antibody fragments. Proc Natl Acad Sci USA 90: 6444-6448.
66. Holliger, P., Wing, M., Pound, J.D., Bohlen, H., Winter, G. (1997) Retargeting serum immunoglobulin with bispecific diabodies. Nat Biotechnol 15: 632-636.
67. Holliger P., Manze, O., Span, M., Hawkins, R., Fleischmann, B., Qianghua, L., Wolf, J., Diehl, V., Cochet, O., Winter, G., Bohlen, H. (1999) Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3xantiCEA bispecific diabodies and B7 × anti-CEA bispecific fusion proteins. Cancer Res 59: 2909-2916.
68. Hombach, A., Jung, W., Pohl C., Renner C., Sahin U., Schmits R., Wolf, J., Kapp, U., Diehl, V., Pfreundschuh, M. (1993) A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo. Int J Cancer 55: 830-836.
69. James, N.D., Atherton, P.J., Jones, J., Howie, A.J., Tchekmedyian, S., Curnow, R.T. (2001) A phase II study of the bispecific antibody MDX-H210 (anti-HER2 × CD64) with GM-CSF in HER2+ advanced prostate cancer. Br J Cancer 85: 152-156.
70. Jendreyko, N., Popkov, M., Beerli, R.R., Chung, J., McGavern, D.B., Rader, C., Barbas, C.F. III (2003) Intradiabodies, bispecific, tetravalent antibodies for the simultaneous functional knockout of two cell surface receptors. J Biol Chem 278: 47812-4789.
71. Jendreyko, N., Popkov, M., Rader, C., Barbas, C.F. III (2005) Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo. Proc Natl Acad Sci USA 102: 8293-8298.
72. Jimenez, X., Lu, D., Brennan, L., Persaud, K., Liu, M., Miao, H., Witte, L., Zhu, Z.A. (2005) A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3. Mol Cancer Ther 4: 427-434.
73. Kanerva, A., Hemminki, A. (2005) Adenoviruses for treatment of cancer. Ann Med 37: 33-43.
74. Karawajew, L., Micheel, B., Behrsing, O., Gaestel, M. (1987) Bispecific antibody-producing hybrid hybridomas selected by a fluorescence activated cell sorter. J Immunol Methods 92: 265-270.
75. Keler, T., Graziano, R.F., Mandal, A., Wallace, P.K., Fisher, J., Guyre, P.M., Fanger, M.W., Deo, Y.M. (1997) Bispecific antibody-dependent cellular cytotoxicity of HER2/neu-overexpressing tumor cells by Fcγ receptor type-I expressing effector cells. Cancer Res 57: 4008-4014.
76. Kelly, F.J., Miller, C.R., Buchsbaum, D.J., Gomez-Navarro, J., Barnes, M.N., Alvarez, R.D., Curiel, D.T. (2000) Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro. Clin Cancer Res 6: 4323-4333.
77. Kipriyanov, S.M., Moldenhauer, G., Schuhmacher, J., Cochlovius, B., Von der Lieth, C.W., Matys, E.R., Little, M. (1999) Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics. J Mol Biol 293: 41-56.
78. Kipriyanov, S.M., Cochlovius, B., Schäfer, H. J., Moldenhauer, G., Bähre, A., Le Gall, F., Knackmuss, S., Little, M. (2002) Synergistic antitumor effect of bispecific CD19 × CD3 and CD19 × CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma. J Immunol 169: 137-144.
79. Köhler, G., Milstein, C. (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497.
80. Kontermann, R.E. (2005) Recombinant bispecific antibodies for cancer therapy. Acta Pharmacol Sin 26: 1-9.
81. Kontermann, R.E., Wing, M.G., Winter, G. (1997) Complement recruitment using bispecific diabodies. Nat Biotechnol 15: 629-631.
82. Kontermann, R.E., Korn, T., Jérôme, V. (2002) Recombinant adenoviruses for in vivo expression of antibody fragments. In: Welschof M, Kraus J (eds) Recombinant Antibody Technology for Cancer Therapy: Reviews and Protocols. Methods in Molecular Medicine. Totowa: Humana Press, pp. 421-433.
83. Koolwijk, P., Rozemüller, E., Stad, R.K., de Lau, W.B., Blast, B.J. (1988) Enrichment and selection of hybrid hybridomas by percoll density gradient centrifugation and flurescent-activated cell sorting. Hybridoma 7: 217-225.
84. Koolwijk, P., Spierenburg, G.T., Frasa, H., Boot, J.H., van de Winkel, J.H., Bat, B.J. (1989) Interaction between hybrid mouse monoclonal antibodies and the human high-affinity IgG FcR, huFcγRI, on U937. Involvement of only one of the mIgG heavy chains in receptor binding. J Immunol 143: 1656-1662.
85. Koolwijk, P., Boot, J.H., Griep, R., Bast, B.J. (1991) Binding of human complement subcomponent C1q to hybrid mouse monoclonal antibodies. Mol Immunol 28: 567-576.
86. Korn, T., Nettelbeck, D.M., Völkel, T., Müller, R., Kontermann, R.E. (2004a) Recombinant bispecific antibodies for the targeting of adenoviruses to CEA-expressing tumour cells: a comparative analysis of bacterially expressed single-chain diabody and tandem scFv. J Gene Med 6: 642-651.
87. Korn, T., Muller, R., Kontermann, R.E. (2004b) Bispecific single-chain diabodymediated killing of endoglin-positive endothelial cells by cytotoxic T lymphocytes. J Immunother 27: 99-106.
88. Kostelny, S.A., Cole, M.S., Tso, J.Y. (1992) Formation of a bispecific antibody by the use of leucine zippers. J Immunol 148: 1547-1553.
89. Kraeber-Bodéré, F., Faivre-Chauvet, A., Ferrer, L., Vuillez, F.-P., Brard, P.-Y., Rousseau, C., Resche, I., Devillers, A., Laffont, S., Bardiés, M., Chang, K., Sharkey, R.M., Goldenberg, D.M., Chatal, J.-F., Barbet, J. (2003) Pharmacokinetics and dosimetry studies for optimization of anti-carcinoembryonic antigen × anti-hapten bispecific antibody-mediated pretargeting of iodine-131-hapten in a phase I radioimmunotherapy trial. Clin Cancer Res 9: 3973s-3981s.
90. Krannenborg, M.H., Boerman, O.C., Oosterwijk-Wakka, J.C., de Weijert, M.C., Corstens, F.H., Oosterweijk, E. (1998) Two-step radio-immunotherapy of renal-cell carcinoma xenografts in nuce mice with anit-renal-cell-carcinoma × anti-DTPa bispecific monoclonal antibodies. Int J Cancer 75: 74-80.
91. Kreutz, F.T., Xu, D.Z., Suresh, M.R. (1998) A new method to generate quadromas by electrofusion and FACS sorting. Hybridoma 17: 267-273.
92. Kriangkum, J., Xu, B., Nagata, L.P., Fulton, R.E., Suresh, M.R. (2001) Bispecific and bifunctional single chain recombinant antibodies. Biomol Eng 18: 31-40.
93. Kufer, P., Mack, M., Gruber, R., Lutterbuse, R., Zettl, F., Riethmuller, G. (1997) Construction and biological activity of a recombinant bispecific single-chain antibody designed for therapy of minimal residual colorectal cancer. Cancer Immunol Immunother 45 193-197.
94. Kufer, P., Lutterbuse, R., Baeuerle, P.A. (2004) A revival of bispecific antibodies. Trends Biotechnol 22: 38-44.
95. Kuus-Reichel, K., Knott, C., Sam-Fong, P., Petrella, E., Corvalan, J.R. (1995) Therapy of streptozotocin induced diabetes with a bifunctional antibody that delivers vinca alkaloids to IL-2 receptor positive cells. Autoimmunity 22: 173-181.
96. Lanzavecchia, A., Scheidegger, D. (1987) The use of hybrid hybridomas to target human cytotoxic T lymphocytes. Eur J Immunol 17: 105-111.
97. Le Doussal, J.M., Martin, M., Gruaz-Guyon, A., Gautherot, E., Delaage, M., Barbet, J. (1990) In vitro and in vivo targeting of radiolabeled monovalent and bivalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugates. J Nucl Med 30: 1358-1366.
98. Lewis, L.D., Cole, B.F., Wallace, P.K., Fisher, J.L., Waugh, M., Guyre, P.M., Fanger M. W., Curnow, R.T., Kaufman, P.A., Ernstoff, M.S. (2001) Pharmacokinenicpharmacodynamic relationship of the bispecific antibody MDX-H210 when administered in combination with interferon gamma: a multiple-dose phase-I study in patients with advanced cancer which overexpresses HER-2/neu. J Immunol Methods 248: 149-165.
99. Lindhofer, H., Mocika, R., Steipe, B., Thierfelder, S. (1995) Preferential speciesrestriced heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol 155: 219-225.
100. Link, B.K., Weiner, G.J. (1993) Production and characterization of a bispecific IgG capable of inducing T-cell-mediated lysis of malignant B cells. Blood 81: 3343-3349.
101. Lloyd, F. Jr., Goldrosen, M. (1991) The production of a bispecific anti-CEA, anti-hapten (4-amino-phthalate) hybrid-hybridoma. J Natl Med Assoc 83: 901-904.
102. Löffler, A., Kufer, P., Lutterbüse, R., Zettl, F., Daniel, P.T., Schwenkenbecher, J.M., Riethmüller, G., Dörken, B., Bargou, R.C. (2000) A recombinant bispecific single-chain antibody, CD19 × CD3: induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphoctes. Blood 95: 2089-2103.
103. Lüdher, F., Huang, Y., Dennehy, K.M., Guntermann, C., Müller, I., Winkler, E., Kerkau, T., Ikemizu, S., Davis, S.J., Hanke, T., Hünig, T. (2003) Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J Exp Med 197: 955-966.
104. Lu, D., Kotanides, H., Jimenez, X., Zhou, Q., Persaud, K., Bohlen, P., Witte, L., Zhu, Z. (1999) Acquired antagonistic activity of a bispecific diabody directed against two different epitopes on vascular endothelial growth factor receptor 2. J Immunol Methods 230: 159-171.
105. Lu, D., Jimenez, X., Zhang, H., Wu, Y., Bohlen, P., Witte, L., Zhu, Z. (2001) Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor. Cancer Res 61: 7002-7008.
106. Lu, D., Jimenez, X., Zhang, H., Bohlen, P., Witte, L., Zhu, Z. (2002) Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments. J Immunol Meth 267: 213-226.
107. Lu, D., Jimenez, X., Zhang, H., Atkins, A., Brennan, L., Balderes, P., Bohlen, P., Witte, L., Zhu, Z. (2003) Di-diabody: a novel tetravalent bispecific antibody molecule by design. J Immunol Methods 279: 219-232.
108. Lu, D., Zhang, H., Ludwig, D., Persaud, A., Jimenez, X., Burtrum, D., Balderes, P., Liu, M., Bohlen, P., Witte, L., Zhu, Z. (2004) Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 279: 2856-2865.
109. Lu, D., Zhang, H., Koo, H., Tonra, J., Balderes, P., Prewett, M., Corcoran, E., Mangalampalli, V., Bassi, R., Anselma, D., Patel, D., Kang, X., Ludwig, D.L., Hicklin, D.J., Bohlen, P., Witte, L., Zhu, Z. (2005) A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 280: 19665-19672.
110. Lum, L.G., Davol, P.A. (2005) Retargeting T cells and immune effector cells with bispecific antibodies. Cancer Chemother Biol Response Modif 22: 273-291.
111. Madrenas, J., Chau, L.A., Teft, W.A., Wu, P. W., Jussif, J., Kasaian, M., Carreno, B.M., Ling, V. (2004) Conversion of CTLA-4 from inhibitor to activator of T cells with a bispecific tandem single-chain Fv ligand. J Immunol 172: 5948-5956.
112. Marvin, J.S., Zhu, Z. (2005) Recombinant approaches to IgG-like bispecific antibodies. Acta Pharmacol Sin 26: 649-658.
113. McCall, A.M., Adams, G.P., Amoroso, A.R., Nielsen, U.B., Zhang, L., Horak, E., Simmons, H., Schier, R., Marks, J.D., Weiner, L.M. (1999) Isolation and characterization of an anti-CD16 single-chain Fv fragment and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol 36: 433-445.
114. McCall, A.M., Shahied, L., Amoroso, A.R., Horak, E.M., Simmons, H.H., Nielson, U., Adams, G.P., Schier, R., Marks, J.D., Weiner, L.M. (2001) Increasing the affinity for tumor antigen enhances bispecific antibody cytotoxicity. J Immunol 166: 6112-6117.
115. Merchant, A.M., Zhu, Z., Yuan, J.Q., Goddard, A., Adams, C.W., Presta, L.G., Carter, P. (1998) An efficient route to human bispecific IgG. Nat Biotechnol 16: 677-681.
116. Milstein, C., Cuello, A.C. (1983) Hybrid hybridomas and their use in immunohistochemistry. Nature 305: 537-540.
117. Molema, G., Kroesen, B.J., Helfrich, W., Meijer, D.K.F., de Leij, L.F.M.H. (2000) The use of bispecific antibodies in tumor cell and tumor vasculature directed immunotherapy. J Control Release 64: 229-239.
118. Morandeau, L., Benoist, E., Loussouarn, A., Quadi, A., Lesaec, P., Mougin, M., Faivre-Chauvet, A., Le Boterff, J., Chatal, J.F., Barbet, J., Gestin, J.F. (2005) Synthesis of new bivalent peptides for applications in the affinity enhancement system. Bioconjug Chem 16: 184-193.
119. Morelli, d., Sardini, A., Villa, E., Menard, S., Colnaghi, M.I., Balsari, A. (1994) Modulation of drug-induced cytotoxicity by a bispecific monoclonal antibody that recognizes the epidermal growth factor receptor and doxorubicin. Cancer Immunol Immunother 38: 171-177.
120. Müller, K.M., Arndt, K.M., Strittmatter, W., Plückthun, A. (1998a) The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies. FEBS Lett 422: 259-264.
121. Müller, K.M., Arndt, K.M., Plückthun, A. (1998b) A dimeric bispecific miniantibody combines two specificities with avidity. FEBS Lett 432: 45-49.
122. Nettelbeck, D.M., Miller, D.W., Jérôme, V., Zuzarte, M., Watkins, S.J., Hawkins, R.E., Müller, R., Kontermann, R.E. (2001) Targeting of adenovirus to endothelial cells by a bispecific single-chain diabody directed against the adenovirus fiber knob domain and human endoglin (CD105). Mol Ther 3: 882-891.
123. Nettelbeck, D.M., Rivera, A.A., Kupsch, J., Dieckmann, D., Douglas, J.T., Kontermann, R.E., Alemany, R., Curiel, D.T. (2004) Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA. Int J Cancer 108: 136-145.
124. Nisonoff, A., Rivers, M.M. (1961) Recombination of a mixture of univalent an tibody fragments of different specificity. Arch Biochem Biophys 93: 460-462.
125. Park, S.S., Ryu, C.J., Kang, Y.J., Kashmiri, S. V., Hong, H.J. (2000) Generation and characterization of a novel tetravalent bispecific antibody that binds to hepatitis B virus surface antigens. Mol Immunol 37: 1123-1130.
126. Paulus, H. (1985) Preparation and biomedical applications of bispecific antibodies. Behring Inst Mitt 78: 118-132.
127. Peipp, M., Valerius, T. (2002) Bispecific antibodies targeting cancer cells. Biochem Soc Trans 30: 507-511.
128. Plückthun, A., Pack, P. (1997) New protein engineering approaches to multivalent and bispecific antibody fragments. Immunotechnology 3: 83-105.
129. Pullarkat, V., Deo, Y., Link, J., Spears, L., Marty, V., Curnow, R., Groshen, S., Gee, C., Weber, J.S. (1999) A phase I study of a HER2/neu bispecific antibody with granulocyte-colony-stimulating factor in patients with metastatic breast cancer that overexpresses HER2/neu. Cancer Immunol Immunother 48: 9-21.
130. Ren-Heidenreich, L., Davol, P.A., Kouttab, N.M., Elfenbein, G.J., Lum, L.G. (2004) Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model. Cancer 100: 1095-1103.
131. Repp, R., van Ojik, H.H., Valerius, T., Groenewegen, G., Wieland, G., Oetzel, C., Stockmeyer, B., Becker, W., Eisenhut, M., Steininger, H., Deo, Y.M., Blijham, G.H., Kalden, J.R., van de Winkel, J.G.J., Gramatzki, M. (2003) Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRIxanti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Br J Cancer 89: 2234-2243.
132. Reusch, U., Le Gall, F., Hensel, M., Moldenhauer, G., Ho, A.D., Little, M., Kipriyanov, S.M. (2004) Effect of tetravalent bispecific CD19 × CD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukaemia by autologous T cells. Int J Cancer 112: 509.
133. Reynolds, P.N., Zinn, K.R., Gavrilyuk, V.D., Balyasnikova, I.V., Rogers, B.E., Buchsbaum, D.J., Wang, M.H., Miletich, D.J., Grizzle, W.E., Douglas, J.T., Danilov, S.M., Curiel, D.T. (2000) A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther 2: 562-578.
134. Reynolds, P.N., Nicklin, S.A., Kaliberova, L., Boatman, B.G., Grizzle, W.E., Balyasnikova, I.V., Baker, A.H., Danilov, S.M., Curiel, D.T. (2001) Combined transductional and transcriptional targeting improves the specificity of transgene expression in vivo. Nat Biotechnol 19: 838-842.
135. Ridgeway, J.B., Presta, L.G., Carter, P. (1996) "Knobs-into-holes" engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng 9: 617-621.
136. Ruf, P., Lindhofer, H. (2001) Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98: 2526-2534.
137. Russell, J.H., Ley, T.J. (2002) Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 20: 323-370.
138. Russoniello, C., Soomasundaram, C., Schlom, J., Deo, Y.M., Keler, T. (1998) Characterization of a novel bispecific antibody that mediates Fcγ receptor type-Idependent killing of tumor-ass ociated glycoprotein-72-expressing tumor cells. Clin Cancer Res 4: 2237-2243.
139. Sanz, L., Blanco, B., Àlvarez-Vallina, L. (2004) Antibodies and gene therapy: teaching old "magic bullets" new tricks. Trends Immunol 25: 85-91.
140. Schlenzka, J., Moehler, T.M., Kipriyanov, S. M., Kornacker, M., Benner, A., Bahre, A., Stassar, M.J., Schafer, H.J., Little, M., Goldschmidt, H., Cochlovius, B. (2004) Combined effect of recombinant CD19 × CD16 diabody and thalidomide in a preclinical model of human B cell lymphoma. Anticancer Drugs 15: 915-919.
141. Schlereth, B., Fichtner, I., Lorenczewski, G., Kleindienst, P., Brischwein, K., da Silva, A., Kufer, P., Lutterbüse, R., Juhnhahn, I., Kasimir-Bauer, S., Wimberger, P., Kimmig, R., Baeuerle, P.A. (2005) Eradication of tumors from a human colon cancer cell line and from ovarian cancer metastases in immunodeficient mice by a single-chain Ep-CAM-/CD3-bispecific antibody construct. Cancer Res 65: 2882-2889.
142. Schneider, M.A., Bruhl, H., Wechselberger, A., Cihak, J., Stangassinger, M., Schlondorff, D., Mack, M. (2005) In vitro and in vivo properties of a dimeric bispecific single-chain antibody IgG-fusion protein for depletion of CCR2(+) target cells in mice. Eur J Immunol 35: 987-995.
143. Schoonjans, R., Willems, A., Schoonooghe, S., Fiers, W., Grooten, J., Mertens, N. (2000) Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives. J Immunol 165: 7050-7057.
144. Segal, D.M., Weiner, G.J., Weiner, L.M. (1999) Bispecific antibodies in cancer therapy. Curr Opin Immunol 11: 558-562.
145. Sforzini, S., Bolognesi, A., Meazza, R., Marciano, S., Casalini, P., Durkop, H., Tazzari, P.L., Stein, H., Stirpe, F., Ferrini, S. (1995) Differential sensitivity of CD30+ neoplastic cells to gelonin delivered by anti-CD30/anti-gelonin bispecific antibodies. Br J Haematol 90: 572-577.
146. Shahied, L.S., Tang, Y., Alpaugh, R.K., Somer, R., Greenspon, D., Weiner, L.M. (2004) Bispecific minibodies targeting (HER2/neu and CD16 exhbit improved tumor lysis when placed in a divalent tumor antigen binding format. J Biol Chem 279: 53907-53914.
147. Shalaby, M.R., Shepard, H.M., Presta, L., Rodrgues, M.L., Beverley, P.C.L., Feldmann, M., Carter, P. (1992) Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protoncogene. J Exp Med 175: 217-225.
148. Sharkey, R.M., Karracay, H., Cardillo, T.M., Chang, C.H., McBride, W.J., Rossi, E.A., Horak, I.D., Goldenberg, D.M. (2005a) Improving the delivery of radionuclides for imaging and therapy of cancer using pretargeting methods. Clin Cancer Res 11: 7109s-7121s.
149. Sharkey, R.M., Karracay, H., Chang, C.H., McBride, W.J., Horak, I.D., Goldenberg, D. M. (2005b) Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new antiCD20 bispecific antibody. Leukemia 19: 1064-1069.
150. Smith, W., Jarrett, A.L., Beattie, R.E., Corvalan, J.R. (1992) Immunoglobulins secreted by a hybrid-hybridoma: analysis of chain assemblies. Hybridoma 11: 87-98.
151. Staerz, U.D., Bevan, M.J. (1986) Hybrid hybridoma producing a bispecific monoclonal antibody that can focus effector T-cell activity. Proc Natl Acad Sci USA 83: 1453-1457.
152. Stockmeyer, B., Elsässer, D., Dechant, M., Repp, R., Gramatzki, M., Glennie, M.J., van de Winkel, J.G.J., Valerius, T. (2001) Mechanisms of G-CSF-or GM-CSFstimulated tumor cell killing by Fc receptor-directed bispecific antibodies. J Immunol Methods 248: 103-111.
153. Sundarapandiyan, K., Keler, T., Behnke, D., Engert, A., Barth, S., Matthey, B., Deo, Y. M., Graziano, R.F. (2001) Bispecific antibody-mediated destruction of Hodgkin's lymphoma cells. J Immunol Methods 248: 113-123.
154. Tacke, M., Hanke, G., Hanke, T., Hunig, T. (1997) CD28-mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: evidence for functionally distinct forms of CD28. Eur J Immunol 27: 239-247.
155. Tillman, B.W., Hayes, T.L., de Gruijl, T.D., Douglas, J.T., Curiel, D.T. (2000) Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Cancer Res 60: 5456-5463.
156. Tutt, A., Greenman, J., Stevenson, G.T., Glennie, M.J. (1991) Bispecific F(ab′γ)3 antibody derivatives for redirecting unprimed cytotoxic T cells. Eur J Immunol 21: 1351-1358.
157. Tutt, A.L., Reid, R., Wilkins, B.S., Glennie, M.J. (1995) Activation and preferential expansion of rat cytotoxic (CD8) T cells in vitro and in vivo with a bispecific (anti-TRC α/β× anti-CD2) F(ab′)2 antibody. J Immunol 155: 2960-2971.
158. Valerius, T., Würflein, D., Stockmeyer, B., Repp, R., Kalden, J.R., Gramatzki, M. (1997) Activated neutrophils as effector cells for bispecific antibodies. Cancer Immunol Immunother 45: 142-145.
159. van de Winkel, J.G.J., Bast, B., de Gast, G.C. (1997) Immunotherapeutic potential of bispecific antibodies. Immunol Today 12: 562-564.
160. van Spriel, A.B., van Ojik, H.H., van de Winkel, J.G.J. (2000) Immunotherapeutic perspective for bispecific antibodies. Immunol Today 21: 391-396.
161. Völkel, T., Korn, T., Bach, M., Müller, R., Kontermann, R.E. (2001) Optimized linker sequences for the expression of monomeridc and dimeric bispecific single-chain diabodies. Protein Eng 14: 815-823.
162. Wallace, P.K., Kaufman, P.A., Lewis, L.D., Keler, T., Givan, A.L., Fisher, J.L., Waugh, M.G., Wahner, A.E., Guyre, P.M., Fanger, M.W., Ernstoff, M.S. (2001) Bispecific antibody-targeted phagocytosis of HER-2/neu expressing tumor cells by myeloid cells activated in vivo. J Immunol Methods 248: 167-182.
163. Walther, W., Stein, U. (2000) Viral vectors for gene transfer: a review of theiruse in the treatment of human diseases. Drugs 60: 249-271.
164. Warnaar, S.O., de Paus, V., Lardenoije, R., Machielse, B.N., de Graaf, J., Bregonje, M., van Haarlem, H. (1994) Purification of bispecific F(ab′)2 from murine trinoma OC/TR with specificity for CD3 and ovarian cancer. Hybridoma 13: 519-526.
165. Watkins, S.J., Mesyanzhinov, V.V., Kurochkina, L.P., Hawkins, R.E. (1997) The "adenobody" approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther 4: 1004-1012.
166. Weiner, L.M., Clark, J.I., Davey, M., Li, W.S., Garcia de Palazzo, I., Ring, D.B., Alpaugh, R.K. (1995) Phase I trial of 2B1: a bispecific monoclonal antibody targeting cerbB-2 and FcγRIII. Cancer Res 55: 4586-4593.
167. Withoff, S., Helfrich, W., de Leij, L.F.M.H., Molema, G. (2001) Bi-sepcific antibody therapy for the treatment of cancer. Curr Opin Mol Ther 3: 53-62.
168. Wolf, E., Hofmeister, R., Kufer, P., Schlereth, B., Baeuerle, P.A. (2005) BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov Today 10: 1237-1244.
169. Würdinger, T., Verheije, M.H., Raaben, M., Bosch, B.J., de Haan, C.A., van Beusechem, V.W., Rottier, P.J., Gerritsen, W.R. (2005) Targeting non-human coronaviruses to human cancer cells using a bispecific single-chain antibody. Gene Ther 12: 1394-1404.
170. Wuest, T., Moosmayer, D., Pfizenmaier, K. (2001) Construction of a bispecific single chain antibody for recruitment of cytotoxic T cells to the tumour stroma associated antigen fibroblast activation protein. J Biotechnol 92: 159-168.
171. Zeidler, R., Mysliwietz, J., Csanady, M., Walz, A., Ziegler, I., Schmitt, B., Wollenberg, B., Lindhofer, H. (2000) The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 83: 261-266.
172. Zeidler, R., Mayer, A., Gires, O., Schmitt, B., Mack, B.M., Lindhofer, H., Wollenberg, B., Walz, A. (2001) TNFα contributes to the antitumor activity of a bspecific, trifunctional antibody. AntiCancer Res 21: 3499-3503.
173. Xie, Z., Shi, M., Feng, J., Yu, M., Sun, Y., Shen, B., Guo, N. (2003) A trivalent antierbB2/anti-CD16 bispecific antibody retargeting NK cells against human breast cancer cells. Biochem Biophys Res Commun 311: 307-312.
174. Xie, Z., Guo, N., Yu, M., Hu, M., Shen, B. (2005) A new format of bispecific antibody: highly efficient heterodimerization, expression and tumor cell lysis. J Immunol Methods 296: 95-101.
175. Zhu, Z., Presta, L.G., Zapata, G., Carter, P. (1997) Remodeling domain interfaces to enhance heterodimer formation. Protein Sci 6: 781-788.
176. Zuo, Z., Jimenez, X., Witte, L., Zhu Z. (2000) An efficient route to the production of an IgG-like bispecific antibody. Protein Eng 13: 361-367.